Zhengchen Yu, Wenjuan Shen, Guochun Lou, Yan Li, Ziming Xie, Jun Ye
{"title":"作者对“基于粪便分子药敏试验的定制铋四联疗法(克拉霉素或呋喃唑酮)在一线幽门螺杆菌根除治疗中更有效吗?”一项三组、多中心随机临床试验","authors":"Zhengchen Yu, Wenjuan Shen, Guochun Lou, Yan Li, Ziming Xie, Jun Ye","doi":"10.1111/hel.70049","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>We appreciate the valuable comments and thoughtful critique offered by the reader regarding our study on tailored bismuth quadruple therapy based on fecal molecular susceptibility testing in first-line <i>Helicobacter pylori</i> eradication. In our response, we have sought to clarify the methodological rationale underlying our statistical analysis and terminology usage, particularly regarding superiority and non-inferiority testing. We have also addressed concerns regarding assessing prior macrolide exposure, outlining the practical considerations that informed our study design. We trust that our clarifications will help to elucidate the study's context and findings further, and we welcome continued academic dialogue on this important topic.</p>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 3","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial”\",\"authors\":\"Zhengchen Yu, Wenjuan Shen, Guochun Lou, Yan Li, Ziming Xie, Jun Ye\",\"doi\":\"10.1111/hel.70049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>We appreciate the valuable comments and thoughtful critique offered by the reader regarding our study on tailored bismuth quadruple therapy based on fecal molecular susceptibility testing in first-line <i>Helicobacter pylori</i> eradication. In our response, we have sought to clarify the methodological rationale underlying our statistical analysis and terminology usage, particularly regarding superiority and non-inferiority testing. We have also addressed concerns regarding assessing prior macrolide exposure, outlining the practical considerations that informed our study design. We trust that our clarifications will help to elucidate the study's context and findings further, and we welcome continued academic dialogue on this important topic.</p>\\n </div>\",\"PeriodicalId\":13223,\"journal\":{\"name\":\"Helicobacter\",\"volume\":\"30 3\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Helicobacter\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hel.70049\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.70049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial”
We appreciate the valuable comments and thoughtful critique offered by the reader regarding our study on tailored bismuth quadruple therapy based on fecal molecular susceptibility testing in first-line Helicobacter pylori eradication. In our response, we have sought to clarify the methodological rationale underlying our statistical analysis and terminology usage, particularly regarding superiority and non-inferiority testing. We have also addressed concerns regarding assessing prior macrolide exposure, outlining the practical considerations that informed our study design. We trust that our clarifications will help to elucidate the study's context and findings further, and we welcome continued academic dialogue on this important topic.
期刊介绍:
Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.